Daiichi Sankyo

Astellas forecasts big sales growth as prostate drug catches hold

Astellas forecasts big sales growth as prostate drug catches hold

Fierce Pharma

Encouraging Phase 1 data with lead compound, ARQ 092, to be presented at AACR

Encouraging Phase 1 data with lead compound, ARQ 092, to be presented at AACR

Yahoo

Latest Tivantinib Failure Hits ArQule Despite Its Irrelevance

Latest Tivantinib Failure Hits ArQule Despite Its Irrelevance

Seeking Alpha

ArQule: An Inexpensive And Well-Financed Oncology Opportunity

ArQule: An Inexpensive And Well-Financed Oncology Opportunity

Seeking Alpha

ArQule stock plunges as lung cancer study shelved

ArQule stock plunges as lung cancer study shelved

Yahoo/AP

Lilly heart drug Effient fails to carve new niche

Lilly heart drug Effient fails to carve new niche

Reuters

TRILOGY At ESC: No Advantage For Prasugrel Over Clopidogrel In Medical ACS Patients

TRILOGY At ESC: No Advantage For Prasugrel Over Clopidogrel In Medical ACS Patients

Forbes

China Biotech In Review: Fidelity Starts New VC Fund For China Healthcare

China Biotech In Review: Fidelity Starts New VC Fund For China Healthcare

Seeking Alpha

Cyclacel: An Intriguing Long Shot

Cyclacel: An Intriguing Long Shot

Seeking Alpha

7 Cancer Drug Stocks to Know Right Now

7 Cancer Drug Stocks to Know Right Now

Seeking Alpha